Last reviewed · How we verify
3-5% acetic acid
At a glance
| Generic name | 3-5% acetic acid |
|---|---|
| Sponsor | University of British Columbia |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Headache
- Upper Respiratory Tract Infection
- Constipation
- Diarrhoea
- Anemia
- Diarrhea
- Flatulence
- Fatigue
- Decreased Appetite
- Oropharyngeal Pain
- Nausea
- Pain
Key clinical trials
- Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia (PHASE1)
- Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia (PHASE1)
- Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma (PHASE1)
- Validation of a Lab-free Low-cost Screening Test for Prevention of Cervical Cancer (NA)
- Single Visit Clinical Validation of ScreenFire, a Low-cost HPV Test (NA)
- Pocket Colposcopy Using CARE Algorithm (NA)
- Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer (PHASE1)
- Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 3-5% acetic acid CI brief — competitive landscape report
- 3-5% acetic acid updates RSS · CI watch RSS
- University of British Columbia portfolio CI